Relevant Interviews, Disease and Trial Updates and Stock-Markets News posted by CRISPR Medicine News.
Always stay updated with the free CMN Newsletter.
Main focus: Treatment of genetic diseases using in vivo gene editing
Company stage: Pre-clinical
Diseases (gene editing): Liver diseases, other genetic diseases
Genome editing tool: ARCUS Meganuclease
Funding stage: Private
Location: Philidelphia, PA, USA
Gene editing partnerships: Precision Biosciences
iECURE develops novel medicines to treat liver diseases and other genetic diseases. The company has licensed Precision Biosciences' ARCUS Meganuclease gene-editing technology for the development of treatments targeting the PCSK9 gene as well as other targets.